key: cord-1037665-5x6wkf97
authors: Shao, Guoliang; Huang, Shaolei; Cui, Yuying; Yang, Dianhui
title: Maxingshigan decoction for treating COVID-19: A protocol for systematic review and meta analysis
date: 2020-11-25
journal: Medicine (Baltimore)
DOI: 10.1097/md.0000000000023224
sha: 309ebbd4a101255939d545e44ca094b705cd4ae4
doc_id: 1037665
cord_uid: 5x6wkf97

BACKGROUND: Coronavirus disease 2019 (COVID-19) is a rapidly spreading disease that has been in a public health emergency of international concern since its outbreak in 2020. Due to the complex pathogenesis and susceptibility of COVID-19, many commonly used drugs for the treatment of COVID-19 have not shown excellent clinical effects. Traditional Chinese medicine has a long clinical history of preventing and treating this respiratory infectious disease. Maxingshigan Decoction (MXSG) is widely used in China to treat COVID-19. However, there is no comprehensive and systematic evidence on the effectiveness and safety of Maxingshigan Decoction. METHODS: PubMed, EMBASE, Clinical Trials, the Cochrane Library, Sino Med, and China National Knowledge Infrastructure up to September 2020. This study only screens clinical randomized controlled trials on MXSG for COVID-19 to evaluate its efficacy and safety. Data were extracted by 1 investigator and checked by an independent investigator. Review Manager 5.3 software was used for the data analysis. The dichotomous data is represented by relative risk, and the continuous is expressed by mean difference or standard mean difference, eventually the data is synthesized using a fixed effect model or a random effect model depending on whether or not heterogeneity exists. RESULTS: The time from a positive diagnosis to a negative result of 2 consecutive nucleic acid tests (not on the same day), cure rate. The results of our research will be published in a peer-reviewed journal. CONCLUSION: The purpose of this systematic review is to provide new evidence for the effectiveness and safety of Maxingshigan decoction in the treatment of COVID-19. PROSPERO REGISTRATION NUMBER: CRD42020211962.

On December 1, 2019, the first case of Coronavirus Disease 2019 (COVID-19) was confirmed in Wuhan, Hubei Province, China, and COVID-19 has spread rapidly around the world and become a serious public health event endangering human life. [1] [2] [3] On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a pandemic (WHO Declares global emergency as Wuhan coronavirus spreads). This disease is characterized by being highly contagious, and people of all ages are susceptible to infection (WHO). As of September 30, 2020, more than 30,000,000 confirmed COVID-19 cases have been reported to the World Health Organization, including more than 1,000,000 deaths. According to the conclusion drawn by the WHO, there is no effective way to control the COVID-19. [4] According to clinical experience, antiviral drugs and symptomatic and supportive treatment are often used. However, its therapeutic effect still needs further evaluation. [5, 6] Therefore, there is an urgent need to find new treatment methods and measures to prevent disease progression and prevalence. [7] However, traditional Chinese medicine and Chinese herbal medicine have accumulated rich clinical experience and effective formulas in the prevention and treatment of SARS in 2003 and other epidemics (COVID-19). [8, 9] Name of Department and Institution where work was done: Shandong University of Traditional Chinese Medicine, Jinan, China.

Source(s) of financial support in the form of grants: Shandong Province Traditional Chinese Medicine Science and Technology Development Plan Project (2019-1059).

The authors have no conflicts of interest to disclose.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. As the country with the most experience in treating COVID-19 in China, Maxingshigan Decoction has been widely used in confirmed patients. [10] Maxing-shigan Decoction is composed of ephedra, almonds, gypsum, and licorice. It has multiple functions of antiviral, anti-inflammatory, immune regulation, and fever reduction. [11] Animal pharmacological experiments confirmed that the thrombin and Toll-like receptor signaling pathway were suggested to be essential pathways for Maxingshigan Decoction (MXSG) mediated anti-inflammatory effects. [8] Clinical studies have shown that Maxing Shigan Decoction has a very good effect on the treatment of viral influenza. [12] Therefore, we aim to collect all randomized controlled trials on MXSG Decoction in the treatment of COVID-19, and conduct meta-analysis and systematic reviews to provide evidence-based medicine for the treatment of COVID-19.

This systematic review protocol has been registered in the PROSPERO network (No. CRD42020211962). We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement [13] guidelines in this study. As this was a review of published literature, ethics committee approval and patient consent were not required. We will update our protocol for any changes in the entire research process if needed. 

The following electronic databases will be searched from December 2019 to December 2020: MEDLINE, PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure, Wan-fang database, Chinese Scientific Journal Database, Chinese Biomedical Literature Databases, and other databases. All published randomized controlled trials (RCTs) about this topic will be included. Exemplary search strategy of PubMed is listed in Table 1 . According to the difference of databases, keywords may combine with free words and comprehensive search will be performed.

2.4.1. Selection of studies. Import all literatures that meet the requirements into Endnote X9 software. Two reviewers (GS and SH) will independently select the studies. They will check the results with each other. When disagreements occur, a third reviewer (DY) will make the final decision. They will read the full texts of all included studies if necessary. Screening operation will flow the diagram of Figure 1 . If the full literatures are unable to be obtained or related data are incomplete, we will contact the corresponding author.

According to the characteristics of the study, we prepare an excel form for data collection before data extraction. Outcome indicators for eligible studies were independently extracted and filled in the data extraction form by 2 reviewers. The main data extracted are as follows: title, author, year, fund source, sample size, age, sex, duration of disease, interventions, outcome measures, adverse reactions, etc. If there is something unclear, you cannot hesitate to contact authors for more detailed information. The above information was finally cross-checked by 2 reviewers.

The quality assessment of RCTs adopts the risk of bias assessment tool provided by the Cochrane Handbook. The following 7 items, such as random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other bias, are evaluated by 3 grades of "low bias," Table 1 PUBMED search strategy.

Search terms "high bias," and "unclear bias." The discrepancies will get a consistent conclusion by discussing between both reviewers or seeking the third-party consultation. Collaboration will be performed for data synthesis and analysis. The dichotomous data is represented by RR, continuous data is expressed by MD or SMD. The heterogeneity of studies will be evaluated by Q-test and I2statistic with RevMan5.3. The heterogeneity will be deemed as low (I2 < 50%), moderate (50%-75%), and high (I2 > 75%). If there is no heterogeneity (I2 < 50%, P > .1), the data are synthesized using a fixed effect model. Otherwise (I2≥50%, P < .1), a random effect model is used to analyze. Then subgroup analysis will be conducted based on the different causes of heterogeneity. If a meta-analysis cannot be performed, it will be replaced by a general descriptive analysis.

This is the first study to evaluate the clinical effect and safety of Maxing Shigan Decoction on patients infected with COVID-19.

With the advent of winter in the northern hemisphere, many experts predict that the epidemic caused by COVID-19 will once again erupt globally. [14] [15] [16] Chinese herbal medicine has unique advantages in the treatment of acute infectious diseases, such as malaria and SARS. [17] During the COVID-19 epidemic, MXSG Decoction played a significant role in improving lung function. This study aims to comprehensively evaluate the effectiveness and safety of MXSG Decoction in the treatment of COVID-19, and to provide more methods for the treatment of COVID-19.

Conceptualization: Dianhui Yang. 

SARS-CoV-2 and COVID-19: from the bench to the bedside

Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review

Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): in silico and experimental study

Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective

Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP)

Traditional Chinese medicine for COVID-19 treatment

Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Preliminary analysis of relationships between COVID19 and climate morphology, and urbanization in the Lombardy region (Northern Italy)

Multiple drivers of the COVID-19 spread: the roles of climate, international mobility, and region-specific conditions

Effect of heat and humidity on the incidence and mortality due to COVID-19 pandemic in European countries

Bioactive ingredients in Chinese herbal medicines that target non-coding RNAs: promising new choices for disease treatment